Collegium Pharma (COLL): Cutting Estimates But Believe Weak Xtampa Volumes Are Temporary - Piper Jaffray
Tweet Send to a Friend
Piper Jaffray analyst, David Amsellem, reiterated his Overweight rating on shares of Collegium Pharmaceutical (NASDAQ: COLL) after reporting 2Q16 financial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
